In COPD, elevated blood eosinophil counts have been recognized as predictors of favorable response to inhaled corticosteroids (ICSs) and, more recently, to biologic therapies targeting interleukin-4 and interleukin-13 (IL-4/13) [22,23,24,25]. The gene discussed is IL13; the disease is chronic obstructive pulmonary disease.